JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

Home・Elenco Azioni・Incyte Corp

Incyte Corp

Chiusa

SettoreSettore sanitario

97.54 0.46

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

96.18

Massimo

97.69

Metriche Chiave
By Trading Economics
Entrata	4.1M 303M
Vendite	-234M 1.3B
P/E Media del settore	13.682 49.8
EPS	1.81
Margine di Profitto	23.834
Dipendenti	2,844
EBITDA	-47M 367M

Raccomandazioni
By TipRanks
Raccomandazioni	Acquista
Previsioni per 12 mesi	+11.51% upside

Dividendi
By Dow Jones
Utili prossimi	28 lug 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	358M 19B
Apertura precedente	97.08
Chiusura precedente	97.54

Notizie sul Sentiment di mercato

By Acuity

25%

75%

110 / 347 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Bullish Evidence

59.52 / 62.66 Supporto e resistenza

Incyte Corp Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

5 mag 2026, 23:43 UTC

Principali Notizie su Eventi

New Zealand's Unemployment Rate Falls in 1Q

5 mag 2026, 23:20 UTC

Azioni calde

Stocks to Watch: AMD, Super Micro, Arista Networks, Freshworks

5 mag 2026, 21:48 UTC

Utili

Suncor Energy Reports Higher 1Q Profit on Increased Oil Production

5 mag 2026, 21:05 UTC

Acquisizioni, Fusioni, Takeovers

Canada Antitrust Watchdog Seeks to Kibosh Keyera Deal for Plains' Canada Gas Business -- 4th Update

6 mag 2026, 00:00 UTC

Discorsi di Mercato

Canada Energy Minister Signals Energy Investments in the Pipeline -- Market Talk

5 mag 2026, 23:39 UTC

Discorsi di Mercato

Gold Rises; Trump Pauses 'Project Freedom' to See if Iran Deal Can Be Finalized -- Market Talk

5 mag 2026, 22:26 UTC

Discorsi di Mercato

AMD Data-Center Business Continues to Surge -- Market Talk

5 mag 2026, 22:20 UTC

Discorsi di Mercato

AMD's AI Revolution is Still in Early Innings, Analysts Say -- Market Talk

5 mag 2026, 22:08 UTC

Utili

Correction to "Palantir Beats Forecasts" on May 4. -- WSJ

5 mag 2026, 22:07 UTC

Utili

AMD Stock Soars on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 mag 2026, 21:48 UTC

Utili

Pan American Silver 1Q Adj EPS $1.09 >PAAS

5 mag 2026, 21:48 UTC

Utili

Pan American Silver 1Q Rev $1.2B >PAAS

5 mag 2026, 21:42 UTC

Utili

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5 mag 2026, 21:38 UTC

Utili

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 mag 2026, 21:30 UTC

Utili

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5 mag 2026, 21:29 UTC

Utili

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 mag 2026, 21:26 UTC

Utili

Strategy Posts Wider Loss as Bitcoin Holdings Hit $64 Billion. The Stock Falls. -- Barrons.com

5 mag 2026, 21:25 UTC

Utili

Alcon Inc. 1Q EPS 39c >ALC.EB

5 mag 2026, 21:25 UTC

Utili

Alcon Inc. 1Q Rev $2.71B >ALC.EB

5 mag 2026, 21:24 UTC

Utili

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 mag 2026, 21:18 UTC

Utili

Mistras Backs 2026 Rev $730M-$750M >MG

5 mag 2026, 21:17 UTC

Utili

AMD Stock Jumps on Solid Earnings. AI Continues to Drive Data Center Chips. -- Barrons.com

5 mag 2026, 21:15 UTC

Utili

Strategy Records Loss of Nearly $13 Billion as Bitcoin Continues Decline -- WSJ

5 mag 2026, 21:12 UTC

Utili

These Stocks Are Today's Movers: Intel, PayPal, Palantir, Shopify, Micron, Duolingo, and More -- Barrons.com

5 mag 2026, 21:11 UTC

Utili

SSR Mining 1Q Rev $581.8M >SSRM

5 mag 2026, 21:10 UTC

Utili

SSR Mining 1Q Adj EPS $1.15 >SSRM

5 mag 2026, 21:10 UTC

Utili

SSR Mining 1Q EPS $1.16 >SSRM

5 mag 2026, 21:08 UTC

Utili

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5 mag 2026, 21:01 UTC

Utili

Intact Financial 1Q EPS C$4.12 >IFC.T

5 mag 2026, 21:01 UTC

Azioni calde

Stocks to Watch Recap: Palantir, AMD, Intel, HSBC -- WSJ

Confronto tra pari

Modifica del prezzo

Incyte Corp Previsione

Obiettivo di Prezzo

By TipRanks

11.51% in crescita

Previsioni per 12 mesi

Media 108.06 USD 11.51%

Alto 135 USD

Basso 75 USD

Basato su 19 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Incyte Corp - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

19 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 19 che hanno fornito valutazioni azionarie a Incyte Corp - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

59.52 / 62.66Supporto e resistenza

Bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

110 / 347 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation